• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
98% Bifida Ferment Lysate
rhSOD (cosmetic grade)
Recombinant humanized collagen
Recombinant Humanized Small-molecule Collagen
Recombinant Humanized Small-molecule Collagen Solution
rhSOD

Divi’s, Gland, Fidelity enter race to buy Orchid Pharma

firstwordpharmaMarch 04, 2019

Tag: Divi’s , Fidelity , Orchid Pharma , Gland

  • The Economic Times reported that Divi's Laboratories, Divi’s Laboratories Gland Celsus Bio Chemicals and Fidelity Trading Corporation have shown preliminary interest in taking over Orchid Pharma.

  • Other bidders keen to acquire the bulk cephalosporin drugmaker include financial investors Everstone, Piramal Capital, AION Capital, ART Capital and Finquest Group.

  • The news comes after the Chennai bench of the National Company Law Tribunal (NCLT) knocked back a proposal by Ingen Capital to take over Orchid Pharma after it failed to bring in the requisite money.

Register as Visitor to CPhI China 2019!

Previous:Pharma Can BMS rebels scuttle its Celgene buy? Analysts do the math—and so far, the votes don't add up

Next:Eli Lilly to launch authorised Humalog generic in the US at 50-percent lower list price

Related News

Prenetics' IM8 Announces Collaboration with Mayo Clinic to Develop New Line of Premium Supplements

PRNewswireDecember 19, 2024

A New Premium Supplements Brand, Launched Officially on November 18th on IM8health.com

PeproMene Bio, Inc. and the Institute for Follicular Lymphoma Innovation Announce $11M Investment to Advance PMB-CT01 (BAFF-R CAR T cell therapy) for Relapsed/Refractory Follicular Lymphoma

PRNewswireDecember 19, 2024

Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration

PRNewswireDecember 20, 2024

Divi’s, Gland, Fidelity enter race to buy Orchid Pharma | Pharmasources.com

Corvia Medical Achieves CE Certification for Atrial Shunt Under New EU MDR Standards

PRNewswireDecember 21, 2024

Corvia Medical, Inc.announced today that it has achieved CE certification for the Corvia® Atrial Shunt System under the latest EU Medical Device Regulations (EU MDR 2017/745).

You may like
More>>

Prostaglandin intermediate17814-85-6

Prostaglandin intermediate17814-85-6
Prostaglandin intermediate69552-46-1

Prostaglandin intermediate69552-46-1
Prostaglandin intermediate865087-08-7

Prostaglandin intermediate865087-08-7
Dinoprost Trometamol/ Prostaglandin F2a Tromethamine

Dinoprost Trometamol/ Prostaglandin F2a Tromethamine
Prostaglandin intermediate69222-61-3

Prostaglandin intermediate69222-61-3
Prostaglandin intermediate81846-26-6

Prostaglandin intermediate81846-26-6
Prostaglandin intermediate54483-30-6

Prostaglandin intermediate54483-30-6
Prostaglandin intermediate60176-16-4

Prostaglandin intermediate60176-16-4
Prostaglandin intermediate59122-46-2

Prostaglandin intermediate59122-46-2
Prostaglandin intermediate83470-76-2

Prostaglandin intermediate83470-76-2

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service